Urinary osteocalcin is a useful marker for monitoring the effect of alendronate therapy

Clinical Chemistry

Volumn 51, Issue 12, 2005, Pages 2362-2365

  Ivaska, Kaisa K ^a   Pettersson, Kim ^a   Nenonen, Arja ^b,c   Uusi Rasi, Kirsti ^b   Heinonen, An ^b   Kannus, Pekka ^b   Kalervo Vaananen H ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b UKK INSTITUTE FOR HEALTH PROMOTION RESEARCH   (Finland)

^c RHEUMATISM FOUNDATION HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITRAL; CITRATE CALCIUM; COLECALCIFEROL; OSTEOCALCIN; PLACEBO;

ADULT; ARTICLE; BONE DENSITY; BONE METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; NORMAL HUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINE LEVEL;

ALENDRONATE; BIOLOGICAL MARKERS; DRUG MONITORING; FEMALE; HUMANS; IMMUNOASSAY; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS; TIME FACTORS;

EID: 28044471766     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.055541     Document Type: Article

References (27)

1. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA 2002;288:1889-97.
2. Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 2000;11(Suppl 6):S66-76.
3. Power MJ, Fottrell PF. Osteocalcin: diagnostic methods and clinical applications. Crit Rev Clin Lab Sci 1991;28:287-335.
4. Lee AJ, Hodges S, Eastell R. Measurement of osteocalcin. Ann Clin Biochem 2000;37:432-46.
5. Taylor AK, Linkhart S, Mohan S, Christenson RA, Singer FR, Baylink DJ. Multiple osteocalcin fragments in human urine and serum as detected by a midmolecule osteocalcin radioimmunoassay. J Clin Endocrinol Metab 1990; 70:467-72.
6. Matikainen T, Käkönen SM, Pettersson K, Karp M, Lövgren T, Väänänen HK, et al. Demonstration of the predominant urine osteocalcin fragments detectable by two-site immunoassays. J Bone Miner Res 1999;14:431-8.
7. Ivaska KK, Heilman J, Likojärvi J, Käkönen SM, Gerdhem P, Åkesson K, et al. Identification of novel proteolytic forms of osteocalcin in human urine. Biochem Biophys Res Commun 2003;306:973-80.
8. Srivastava AK, Mohan S, Singer FR, Baylink DJ. A urine midmolecule osteocalcin assay shows higher discriminatory power than a serum midmolecule osteocalcin assay during short-term alendronate treatment of osteoporotic patients. Bone 2002;31:62-9.
9. Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Heilman J, Isaksson A, et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2004;19:386-93.
10. Cloos PA, Christgau S. Characterization of aged osteocalcin fragments derived from bone resorption. Clin Lab 2004;50:585-98.
11. Ivaska KK, Käkönen SM, Gerdhem P, Obrant KJ, Pettersson K, Väänänen HK. Urinary osteocalcin as a marker of bone metabolism. Clin Chem 2005;51:618-28.
12. Eastell R. Management of osteoporosis due to ovarian failure. Med Pediatr Oncol 2003;41:222-7.
13. Uusi-Rasi K, Kannus P, Cheng S, Sievänen H, Pasanen M, Heinonen A, et al. Effect of alendronate and exercise on bone and physical performance of postmenopausal women: a randomized controlled trial. Bone 2003;33: 132-43.
14. Käkönen SM, Hellman J, Karp M, Laaksonen P, Obrant KJ, Väänänen HK, et al. Development and evaluation of three immunofluorometric assays that measure different forms of osteocalcin in serum. Clin Chem 2000;46: 332-7.
15. Eastell R, Mallinak N, Weiss S, Ettinger M, Pettinger M, Cain D, et al. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res 2000;15:594-8.
16. Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell R, Blumsohn A. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 2004;34:187-94.
17. Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimäki T, Schmidt-Gayk H, et al. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 2005;20:1804-12.
18. Looker AC, Bauer DC, Chesnut CH III, Gundberg CM, Hochberg MC, Klee G, et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 2000;11:467-80.
19. Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 1999;24:237-44.
20. Ravn P, Thompson DE, Ross PD, Christiansen C. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 2003;33: 150-8.
21. Greenspan SL, Resnick NM, Parker RA. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy, a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 2005;90:2762-7.
22. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004;19: 1250-8.
23. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-6.
24. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-700.
25. Chesnut CH III, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995;99:144-52.
26. Åkesson K, Käkönen SM, Josefsson PO, Karlsson MK, Obrant KJ, Pettersson K. Fracture-induced changes in bone turnover: a potential confounder in the use of biochemical markers in osteoporosis. J Bone Miner Metab 2005;23:30-5.
27. Banfi G, Daverio R. In vitro stability of osteocalcin. Clin Chem 1994;40: 833-4.